Health Press Releases & Articles 566 - 570 of 771


Neostem, Inc. Appoints Leading Chinese Medical Official To Its Advisory Board starstarstarstarstar   17th July 2009 - Views: 476 Neostem, Inc. Appoints Leading Chinese Medical Official To Its Advisory Board NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need.

Nswfb And Gio Join Forces To Promote Fire Safety Awareness starstarstarstarstar   16th July 2009 - Views: 395 On Sunday 19 July, the NSW Emergency Services Minister, Steve Whan, will announce a Major Community Partnership between GIO and NSW Fire Brigades (NSWFB).

Analysis Of Edoxaban Phase Ii Data Provides Insight Into Reduced Bleeding Events Seen In Once-daily starstarstarstarstar   16th July 2009 - Views: 364 Analysis Of Edoxaban Phase Ii Data Provides Insight Into Reduced Bleeding Events Seen In Once-daily A sub-analysis of a Phase IIb multinational study(1) with edoxaban(2) -- an investigational oral Factor Xa inhibitor - provides insights into why patients with non-valvular atrial fibrillation (AF) receiving edoxaban once daily (OD) experienced fewer bleeding events than patients given edoxaban twice a day (BID).

Improving Transfusion Safety: Fenwal, Verax Biomedical Sign Agreement For Rapid starstarstarstarstar   15th July 2009 - Views: 328 The Verax PGD(R) test is the only rapid test for the detection of bacteria cleared by the United States Food and Drug Administration (FDA) and CE Marked in Europe.

Accumetrics' Verifynow(r) P2y12 Test Provides Physicians With Information To Assess A Patient's Resp starstarstarstarstar   15th July 2009 - Views: 556 Accumetrics' Verifynow(r) P2y12 Test Provides Physicians With Information To Assess A Patient's Resp With the recent FDA approval of the new P2Y12 inhibitor, prasugrel (Effient), Accumetrics, Inc. announces that its VerifyNow P2Y12 Test is not only able to assess response to Plavix(R), but also its newly approved competitor, Effient.

news articles logo NEWS ARTICLES
Contact News Articles